Published in BJU Int on March 01, 2005
Alpha-blocker use is associated with decreased risk of sexual dysfunction. Urology (2009) 1.42
Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clin Interv Aging (2008) 1.02
Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia. Ther Clin Risk Manag (2011) 0.96
Lower urinary tract symptoms in men. BMJ (2014) 0.95
Current concepts in ejaculatory dysfunction. Rev Urol (2006) 0.87
Effect of patient-optimized doses of tamsulosin on erectile function in men with erectile dysfunction and lower urinary tract symptoms. Korean J Urol (2013) 0.80
Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Ther Clin Risk Manag (2007) 0.78
A systematic review of the correlates and management of nonpremature ejaculatory dysfunction in heterosexual men. Ther Adv Urol (2013) 0.78
Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunction. Ther Adv Urol (2013) 0.75
Ejaculatory dysfunction in the treatment of lower urinary tract symptoms. Transl Androl Urol (2016) 0.75
The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Transl Androl Urol (2017) 0.75
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol (2012) 6.09
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol (2013) 4.89
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol (2010) 4.45
EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol (2004) 3.72
Systematic review of complications of prostate biopsy. Eur Urol (2013) 3.66
MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol (2011) 3.57
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34
Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol (2012) 3.30
Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol (2012) 3.01
The current status of laparoscopic sacrocolpopexy: a review. Eur Urol (2009) 2.85
Hospital admissions after transrectal ultrasound-guided biopsy of the prostate in men diagnosed with prostate cancer: a database analysis in England. Int J Urol (2014) 2.72
Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol (2011) 2.61
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Prospective comparison of radical retropubic prostatectomy and robot-assisted anatomic prostatectomy: the Vattikuti Urology Institute experience. Urology (2002) 2.58
TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int (2013) 2.44
Laparoscopic and robot assisted radical prostatectomy: establishment of a structured program and preliminary analysis of outcomes. J Urol (2002) 2.43
Holmium laser enucleation versus photoselective vaporization for prostatic adenoma greater than 60 ml: preliminary results of a prospective, randomized clinical trial. J Urol (2012) 2.42
A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet (2002) 2.24
Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. Clin Cancer Res (2010) 2.23
The use of a novel reverse thermosensitive polymer to prevent ureteral stone retropulsion during intracorporeal lithotripsy: a randomized, controlled trial. J Urol (2010) 2.20
MR to ultrasound registration for image-guided prostate interventions. Med Image Anal (2010) 2.07
How good is MRI at detecting and characterising cancer within the prostate? Eur Urol (2006) 2.07
Laparoscopic living-donor nephrectomy: analysis of the existing literature. Eur Urol (2010) 2.07
Air cystoscopy is superior to water cystoscopy for the diagnosis of active hematuria. J Urol (2013) 2.06
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol (2012) 2.05
Biotechnology and drug discovery: from bench to bedside. South Med J (2003) 2.04
Molecular lymph node staging in bladder urothelial carcinoma: impact on survival. Eur Urol (2008) 2.04
The immediate and 6-mo reproducibility of pressure-flow studies in men with benign prostatic enlargement. Eur Urol (2007) 2.03
Surgical atlas. Transurethral resection of the prostate. BJU Int (2006) 2.02
Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer. J Urol (2012) 1.99
uPM3, a new molecular urine test for the detection of prostate cancer. Urology (2004) 1.91
Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol (2009) 1.87
The value of a second transurethral resection for T1 bladder cancer. BJU Int (2006) 1.82
The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int (2010) 1.74
Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery. J Clin Epidemiol (2006) 1.73
Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: A proposed standard for the conduct of therapy. BJU Int (2006) 1.68
Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ (2006) 1.66
Influence of blood transfusions during radical retropubic prostatectomy on disease outcome. Urology (2006) 1.64
High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol (2003) 1.63
Photodynamic therapy for prostate cancer--a review of current status and future promise. Nat Clin Pract Urol (2009) 1.62
Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int (2007) 1.61
Training future surgeons for management roles: the resident-surgeon-manager conference. Arch Surg (2012) 1.60
DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. J Urol (2009) 1.59
Extending the application of tubeless percutaneous nephrolithotomy. Urology (2007) 1.59
Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. BJU Int (2012) 1.58
Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol (2003) 1.58
Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. Eur Urol (2010) 1.56
Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy. Eur Urol (2007) 1.55
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int (2011) 1.54
Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment. BMJ (2004) 1.54
Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology (2003) 1.52
Health and quality of life in urology: issues in general urology and urological oncology. Arch Esp Urol (2009) 1.52
Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol (2002) 1.51
The relationship between objective frequency-volume chart data and the I-PSS in men with lower urinary tract symptoms. Eur Urol (2007) 1.51
Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma. BJU Int (2014) 1.49
The influence of family history on prostate cancer risk: implications for clinical management. BJU Int (2010) 1.48
Megameatus intact prepuce hypospadias variant: application of tubularized incised plate urethroplasty. Urology (2005) 1.47
Extraperitoneal standard laparoscopic radical prostatectomy. J Endourol (2004) 1.47
A description of radical nephrectomy practice and outcomes in England: 1995-2002. BJU Int (2005) 1.46
Orthotopic kidney transplantation: an alternative surgical technique in selected patients. Eur Urol (2010) 1.45
Focal therapy for prostate cancer: a potential strategy to address the problem of overtreatment. Arch Esp Urol (2010) 1.44
Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer? BJU Int (2014) 1.44
Focal cryoablation: a treatment option for unilateral low-risk prostate cancer. BJU Int (2013) 1.44
Comparison of the rate, location and size of positive surgical margins after laparoscopic and robot-assisted laparoscopic radical prostatectomy. BJU Int (2011) 1.42
Refinements in treatment of large bladder calculi: simultaneous percutaneous suprapubic and transurethral cystolithotripsy. Urology (2004) 1.41
Validation and comparison of the two Kattan nomograms in patients with prostate cancer treated with (125) iodine brachytherapy. BJU Int (2011) 1.41
Non-contrast computed tomography after percutaneous nephrolithotomy: findings and clinical significance. Urology (2012) 1.41
Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. Radiology (2013) 1.39
Recent advances of natural orifice transluminal endoscopic surgery in urological surgery. Int J Urol (2013) 1.39
Midline dorsal plication technique for penile curvature repair. J Urol (2004) 1.39
Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients: physiological distribution, statistical differences, imaging pearls, and normal variants. Nucl Med Commun (2015) 1.39
Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer. Phys Med Biol (2009) 1.39
Evaluation of erectile function after laparoscopic radical prostatectomy in a single center. Can J Urol (2012) 1.38
Immediate closure of nephrostomy tube wounds using a tissue adhesive: a novel approach following percutaneous endourological procedures. J Urol (2003) 1.38
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int (2011) 1.37
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol (2010) 1.34
Perioperative complications of laparoscopic radical prostatectomy: the Montsouris 3-year experience. J Urol (2002) 1.34
Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol (2007) 1.31
A systematic review and critique of the literature relating hospital or surgeon volume to health outcomes for 3 urological cancer procedures. J Urol (2004) 1.31
The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU Int (2007) 1.30
Dorsal vein injuries observed during penile exploration for suspected penile fracture. J Sex Med (2006) 1.29
Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology (2007) 1.29
Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol (2005) 1.24
Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int (2008) 1.23
Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res (2007) 1.23
Lymphadenectomy in the surgical management of penile cancer. Eur Urol (2009) 1.19
An operative and anatomic study to help in nerve sparing during laparoscopic and robotic radical prostatectomy. Eur Urol (2003) 1.19
Laparoscopic sacral colpopexy approach for genito-urinary prolapse: experience with 363 cases. Eur Urol (2005) 1.19
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol (2012) 1.18
Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol (2006) 1.18
Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging (2012) 1.18
The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation. J Urol (2012) 1.17
Robot-assisted versus pure laparoscopic radical prostatectomy. World J Urol (2006) 1.16
MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology (2008) 1.15
Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol (2006) 1.14
Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology (2004) 1.14